Article Contents ::
- 1 The Brand Name EMYCIN Has Generic Salt :: Erythromycin
- 2 EMYCIN Is From Company Themis Priced :: Rs. 9.41/16.15
- 3 EMYCIN have Erythromycin is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name EMYCIN Has Generic Salt :: Erythromycin
EMYCIN Is From Company Themis Priced :: Rs. 9.41/16.15
EMYCIN have Erythromycin is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
|Brand Name||Company / Manufacturers||Strength||Unit||Price / 30/60;ML|
|Company Brand Name||Salt Combination||Main Medical Class||Sub Medical Class|
|From Themis :: EMYCIN||Erythromycin||#N/A||#N/A|
Indications for Drugs ::
Susceptible infections, Respiratory tract infections, Enteritis, Pertussis, Trench fever, Chanroid, Chlamydial infections, Diphtheria, Legionnaire’s disease, Pneumonia, Sinusitis, Bronchitis, Acne, Rheumatic fever, Neonatal conjunctivitis.
Drug Dose ::
Adults: Usually 250 mg every 6 hours, or 500 mg every 12 hours. May increase up to 4 g/day, according to severity of infection. Upper respiratory tract infections of mild to moderate severity: 250 to 500 mg 4 times a day for 10 days. Lower respiratory infections of mild to moderate severity: 250 to 500 mg 4 times a day for 10 days. Respiratory tract infections due to Mycoplasma pneumoniae: 500 mg 6 hours for 5 to 10 days, treat severe infections for up to 3 weeks. Skin and soft tissue infections of mild to moderate severity: 250 to 500 mg 4 times a day for 10 days. Pelvic inflammatory diseases (PID), acute due to Neisseria gonorrhoeae: 500 mg 4 times a day for 10 to 14 days. Urogenital infection during pregnancy caused by Chlamydia trachomatis: 500 mg 4 times daily for 7 days or 250 mg 4 times daily for 14 days. Urethral, endocervical or rectal infections, uncomplicated: 500 mg 4 times daily for 7 days or 250 mg 4 times daily for 14 days. Non-gonococcal urethritis: 500 mg 4 times daily for at least 7 days. Neisseria gonorrhoeae: Uncomplicated urethral, endocervical or rectal infections and in penicillinase producing N. gonorrhoeae(PPNG): 500 mg 4 times a day for 7 days. Early syphillis (primary, secondary or latent syphillis of < 1 year duration): 500 mg 4 times a day for 14 days. Severe or chronic diarrhoea: 500 mg 4 times a day for 7 days. Rheumatic fever: 250 mg 2 times daily. Bacterial endocarditis: 1 g 2 hours prior to procedures, then 500 mg 6 hours after initial dose. Acne: 500 mg twice daily for 3 months reduced to 250 mg twice for 3 months. Children: The usual oral dose is 30-50 mg/kg body weight per day in divided doses. For more severe infections, the dose may be doubled. Contraindication ::
Hypersensitivity; porphyria; hepatic impairment; pregnancy.
Drug Precautions ::
Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis.
Drug Side Effects ::
Rash, urticaria; nausea, vomiting, GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis. Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.
Pregnancy category ::
Drug Mode of Action ::
Erythromycin inhibits protein synthesis by irreversibly binding to the 50S ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.
Drug Interactions ::
May decrease plasma levels of valproic acid thus, increasing the risk of seizures. Increased plasma concentrations w/ probenecid.